Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
MARQUEE: Tivantinib + Erlotinib in Non-Squamous NSCLC
NCT01244191Phase 3Terminated
- Sponsor
- Daiichi Sankyo Co., Ltd.
- Start
- Jan 2011
- Primary completion
- Dec 2012
- Modality
- Small Molecules
- Countries
- 23
01
Overview
A Phase 3 trial of tivantinib in Nonsquamous Non-Small Cell Lung Cancer (nsNSCLC), sponsored by Daiichi Sankyo Co., Ltd.. Started Jan 2011; status: terminated.
02
Drugs
tivantinib
03
Conditions
Nonsquamous Non-Small Cell Lung Cancer (nsNSCLC)
Beyond the preview
Go deeper on NCT01244191.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT01244191.